Gyre Therapeutics, Inc. Common Stock (GYRE) — Analysis Summary
Gyre Therapeutics, Inc. Common Stock (GYRE) has a market cap of $727.92M with year-over-year revenue growth of +10.2%. Net margin stands at 8.5%. The stock trades at a P/E ratio of -25.8.
Key Takeaways
- Revenue changed +10.2% year-over-year
- Net margin of 8.5%
- P/E ratio of -25.8
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, GYRE posted revenue growth of +10.2% and trades at a P/E of -25.8.
Gyre Therapeutics, Inc. Common Stock (GYRE)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Net income turned negative after a profitable prior period.
Operating margin at -21.7% — material operating losses
Net margin at -23.3% — significant losses
The latest filing shows negative free cash flow.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
618
Headquarters
SAN DIEGO, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
N/A
Dividend Yield
N/A
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.